NIKKEI 225
36,888.43 -1,191.27 (-3.13%) HANG SENG
16,188.77 -197.10 (-1.20%) CRUDE OIL
85.80 +3.07 (+3.71%) GOLD FUTURES
2,427.30 +29.30 (+1.22%) DOW
37,775.38 +22.07 (+0.06%) Bitcoin GBP
48,560.37 -1,080.71 (-2.18%)
Ionis Pharmaceuticals, Inc. (IONS)
After hours:
- PR Newswire
Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced full results from the Phase 3 Balance study of Ionis' lead independent investigational medicine, olezarsen, for the treatment of adults with familial chylomicronemia syndrome (FCS). The olezarsen 80 mg monthly dose met the primary endpoint of significantly reducing triglycerides (TGs) in patients with genetically validated FCS at six months. In addition, olezarsen demonstrated robust and sustained reductions in TGs and serum apolipoprote
- PR Newswire
Ionis to present at upcoming investor conferences
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences:
- PR Newswire
Ionis to hold olezarsen Phase 3 data webcast
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Monday, April 8th at 10:00 a.m. Eastern Time to discuss the olezarsen Phase 3 Balance study results in patients with familial chylomicronemia syndrome (FCS) presented at the 2024 American College of Cardiology Annual Meeting.
